Welcome to our dedicated page for Titan Pharmaceut news (Ticker: TTNP), a resource for investors and traders seeking the latest updates and insights on Titan Pharmaceut stock.
Titan Pharmaceuticals Inc (TTNP) delivers innovative therapeutic solutions through its proprietary ProNeura™ continuous drug delivery platform. This page consolidates official updates and analysis on the company's progress in treating chronic conditions including opioid dependence.
Investors and healthcare professionals will find timely updates on regulatory milestones, clinical developments, and strategic partnerships. Our curated news collection covers essential updates including product approvals, research advancements, and operational developments relevant to TTNP's biopharmaceutical pipeline.
Key focus areas include Probuphine® maintenance therapy innovations, ProNeura™ technology applications in new therapeutic areas, and FDA regulatory communications. All content undergoes verification to ensure accuracy and relevance for stakeholders monitoring long-term treatment solutions.
Bookmark this page for direct access to TTNP's latest developments in sustained-release medication technologies and chronic disease management advancements. Check regularly for verified updates that matter to informed decision-making in biopharmaceutical investments.
Titan Pharmaceuticals (NASDAQ: TTNP) has completed a $1 million private placement through the sale of Series B Convertible Preferred Stock to Blue Harbour Asset Management. The agreement involves the purchase of 100,000 preferred shares at a conversion price of $3.00.
The deal includes a beneficial ownership conversion blocker that prevents Blue Harbour from acquiring more than 19.99% of Titan's outstanding common stock or the maximum percentage permissible under Nasdaq rules without shareholder approval. The shares were sold through a private placement under Regulation S of the Securities Act.
The companies have also entered into a registration rights agreement, with ARC Group serving as the sole financial advisor for the transaction.
Titan Pharmaceuticals (NASDAQ: TTNP) has received two notices from Nasdaq regarding listing compliance issues. The first notice on November 22, 2024, concerns the company's failure to file its Q3 2024 Form 10-Q on time. Titan has until January 21, 2025, to submit a compliance plan and may receive up to 180 days (until May 19, 2025) to file the report. The second notice on November 25, 2024, addresses non-compliance with audit committee requirements following Brynner Chiam's appointment. The company has until November 6, 2025, to resolve this issue and plans to appoint an additional independent director to the Board and Audit Committee.
Titan Pharmaceuticals (NASDAQ: TTNP) has entered into a Merger Agreement with KE Sdn. Bhd. for a reverse merger transaction. The deal involves a two-step process: TTNP Merger Sub will merge with Titan, making Titan a wholly-owned subsidiary of BSKE KE shareholders can then exchange their shares for BSKE ordinary shares. Post-merger, KE and Titan shareholders are expected to own 86.7% and 13.3% of the combined company, respectively. Dato' Seow Gim Shen, Titan's CEO and KE's major shareholder, will own 48.9% of the combined entity. The merger aims to create value for Titan stockholders by combining with KE, a distributor of human capital management solutions in Asia Pacific. The deal is subject to stockholder approval, Nasdaq listing approval, and other customary conditions.
Titan Pharmaceuticals (NASDAQ: TTNP) has signed a non-binding letter of intent for a proposed reverse merger with a notable Advanced Air Mobility (AAM) developer. CEO David E. Lazar highlighted the growth potential in the AAM sector while indicating progress in strategic transactions. The merger is contingent upon several factors, including board and shareholder approval, and raising additional financing to maintain Nasdaq listing. Despite the optimistic tone, there is uncertainty surrounding the completion of the merger, and the letter of intent offers no guarantees for finalization.
Titan Pharmaceuticals has granted an exclusive license to Ocular Therapeutix for ophthalmic uses of certain patent applications in the U.S. This agreement includes an upfront licensing fee and potential milestone payments. Dr. Kate Beebe DeVarney, President and COO of Titan, expressed satisfaction with the deal, highlighting the company's efforts to monetize its scientific assets. Titan focuses on using its ProNeura® drug delivery technology to develop therapeutics for chronic conditions, aiming to enhance shareholder value.
FAQ
What is the current stock price of Titan Pharmaceut (TTNP)?
What is the market cap of Titan Pharmaceut (TTNP)?
